MUMBAI, India, July 13 -- Intellectual Property India has published a patent application (202617076216 A) filed by Arrowhead Pharmaceuticals, Inc. on June 19, 2026, for Rnai Agents For Inhibiting Expression Of Activin Receptor-Like Kinase 7 (alk7), Compositions Thereof, And Methods Of Use.
Inventors include Ngai, Michelle; Majewski, Mark; Ding, Zhi-Ming; Glebocka, Agnieszka; Pei, Tao; Hamilton, James Number; and Shekhtman, Grigoriy.
The application for the patent was published on July 10, 2026, under issue no. 28/2026.
Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an Activin Receptor-Like Kinase 7 (ALK7) gene. The ALK7 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an ALK7 gene. Pharmaceutical compositions that include one or more ALK7 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described ALK7 RNAi agents to adipose tissue, in vivo, provides for inhibition of ALK7 gene expression and a reduction in ALK7 activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including obesity, diabetes, or insulin resistance.
Disclaimer: Curated by HT Syndication.
